Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
IPO Year: 2018
Exchange: NASDAQ
Website: biofrontera.com
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the "Company") (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, decided today its American Depositary Shares ("ADS") should be delisted from the Nasdaq Capital Market ("Nasdaq") and its reporting obligations with the Securities and Exchange Commission ("SEC") should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (OTC:BFFTF) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, announces that two clinical studies for its prescription drug Ameluz® in the United States are being started with site initiations currently in progress, seven sites for the phase two study for the treatment of moderate- to- severe acne in adults as well as eight sites for the phase I safety study evaluating the safety of photodynamic therapy (PDT) with the simultaneous application of three tubes of Ameluz®. "Both studies are focused on optimizing market positioning and expanding market share for our FDA-approved
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:00 am ET)Dial-in number Germany: +49 69201744220Conference code: 35058739# In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference co
Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today announced the approval of the new red-light source for photodynamic therapy (PDT), the BF-RhodoLED® XL, by the U.S. Food and Drug Administration (FDA). In accordance with FDA requirements, the approval was granted as a combination approval with our prescription drug Ameluz®, same as the approval with the predecessor model BF-RhodoLED®. The new, larger BF-RhodoLED® XL was approved in combination with Ameluz® for the treatment of mild and moderate actinic keratoses on the face and scalp, which corresponds to t
Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021. The Company's preliminary, unaudited revenue from product sales in September 2021 was in the range of EUR 2.3 and 2.5 million, compared to EUR 1.8 million in September 2020, an increase of about 33%. Preliminary revenues from product sales in the US were between EUR 1.6 and 1.8 million compared to EUR 1.0 million in September 2020, an increase of about 64%. In Germany, revenues from product sales were in the range of EUR 0.4 and 0.6 mi
Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021. The Company's preliminary, unaudited revenue from product sales in August 2021 amounted to approximately EUR 1,485 thousand, compared to EUR 1,341 thousand in August 2020, an increase of 11%. Preliminary revenues from product sales in the US were around EUR 1,027 thousand compared to EUR 917 thousand in August 2020, an increase of 12%. In Germany, revenues from product sales amounted to approximately EUR 349 thousand, compare
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021. Key financial figures and business performance for the six months ended June 30, 2021 In EUR thousands6M 2021 6M 2020 ChangeRevenue13,09416,117-19% thereof from product sales13,0949,676+35%Gross profit on sales11,08214,625-24%Research and development costs(2,921)(2,389)+22%General and administrative costs(5,553)(4,413)+26%Sales and marketing costs(10,191)(12,151)-16%Profit (loss) on operations(7,583)(4,327)+75%EBITDA(5,768)(697)+7
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 63828444# In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 78540812# Plea
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:00 am ET)Dial-in number Germany: +49 69201744220Conference code: 35058739# In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference co
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 63828444# In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 78540812# Plea
3 - Biofrontera AG (0001712641) (Reporting)
-Reuters
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.4 million. Biofrontera (NASDAQ:BFRA) shares rose 17.21% to $3.2. The market value of their outstanding shares is at $90.7 million. Mainz Biomed (NASDAQ:MYNZ) stock moved upwards by 14.19% to $15.45. The company's market cap stands at $212.2 million. Also check this: Tesla And 4 Other Stocks Sold By Insiders Hims & Hers Health (NYSE:HIMS) shares rose 12.61% to $4.73. The company's market cap stands at $969.6 million. As per the press release, Q4 earnings came out yesterday. NanoVibronix (NASDAQ:NAOV) shares incre
Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9 million. Paratek Pharmaceuticals (NASDAQ:PRTK) stock rose 9.76% to $4.27. The market value of their outstanding shares is at $214.3 million. INmune Bio (NASDAQ:INMB) shares increased by 9.38% to $12.0. The market value of their outstanding shares is at $214.1 million. Revelation Biosciences (NASDAQ:REVB) stock rose 7.17% to $2.39. The company's market cap stands at $34.0 million. Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 6.95% to $4.0. The market value of their outstanding shares is at $144.9 millio
Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5 million. The company's, Q1 earnings came out 3 days ago. Biofrontera (NASDAQ:BFRA) stock rose 11.85% to $3.49. The market value of their outstanding shares is at $98.9 million. Paratek Pharmaceuticals (NASDAQ:PRTK) stock rose 9.76% to $4.27. The company's market cap stands at $214.3 million. Revelation Biosciences (NASDAQ:REVB) stock rose 9.41% to $2.44. The market value of their outstanding shares is at $34.7 million. INmune Bio (NASDAQ:INMB) stock rose 9.38% to $12.0. The market value of their outstanding shares is at $21
Biofrontera AG (the “Company”) (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market (“Nasdaq”) and its reporting obligations with the Securities and Exchange Commission (“SEC”) should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the ADS on the U.S. over-the-counter (OTC) market. The ADSs wi
SC 13D/A - Biofrontera AG (0001712641) (Subject)
SC 13D/A - Biofrontera AG (0001712641) (Subject)
SC 13D/A - Biofrontera AG (0001712641) (Subject)
SC 13D/A - Biofrontera AG (0001712641) (Subject)
EFFECT - Biofrontera AG (0001712641) (Filer)
15F-12B - Biofrontera AG (0001712641) (Filer)
POS AM - Biofrontera AG (0001712641) (Filer)
S-8 POS - Biofrontera AG (0001712641) (Filer)
25 - Biofrontera AG (0001712641) (Filer)
6-K - Biofrontera AG (0001712641) (Filer)
6-K - Biofrontera AG (0001712641) (Filer)
6-K - Biofrontera AG (0001712641) (Filer)
6-K - Biofrontera AG (0001712641) (Filer)
6-K - Biofrontera AG (0001712641) (Filer)